Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
Author:
Affiliation:
1. University of Groningen; University Medical Center; Groningen The Netherlands
2. AstraZeneca, Gothenburg; Mölndal Sweden
3. AstraZeneca; Wilmington DE USA
Funder
AstraZeneca
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12654/fullpdf
Reference34 articles.
1. The kidney in type 2 diabetes therapy;Heerspink;Rev Diabet Stud,2011
2. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial;Bailey;Lancet,2010
3. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus;Komoroski;Clin Pharmacol Ther,2009
4. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects;Komoroski;Clin Pharmacol Ther,2009
5. Effects of dapagliflozin on cardiovascular risk factors;Ptaszynska;Postgrad Med,2013
Cited by 164 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is GFR decline induced by SGLT2 inhibitor of clinical importance?;Cardiovascular Diabetology;2024-05-29
2. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21
3. Podocyte-targeted therapies — progress and future directions;Nature Reviews Nephrology;2024-05-09
4. Assessment of effects of combination of SGLT2 inhibitors and renin–angiotensin–aldosterone system blockers on the renal functions of patients of diabetic kidney disease (SGRASS-DKD study);Journal of Diabetology;2024-01
5. Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease;Frontiers in Endocrinology;2023-12-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3